| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |